Perifosine

Generic Name: Perifosine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₅₂NO_₄P

CAS Number: 157716-52-4

Unique Ingredient Identifier: 2GWV496552

Background: Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

Indication: Investigated for use/treatment in solid tumors, multiple myeloma, leukemia (unspecified), lung cancer, and brain cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Phase 1

Completed

Conditions: Anaplastic Astrocytoma
Glioblastoma
Anaplastic Oligodendroglioma
Mixed Glioma
Brain Tumor, Recurrent

Interventions: Procedure: Cytoreductive surgery
Drug: Perifosine
Drug: Temsirolimus

First Posted Date: 2014-09-12

Last Posted Date: 2023-05-25

Lead Sponsor: Andrew B Lassman, MD

Target Recruit Count: 10

Registration Number: NCT02238496

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: perifosine

First Posted Date: 2010-10-20

Last Posted Date: 2018-03-14

Lead Sponsor: AEterna Zentaris

Target Recruit Count: 24

Registration Number: NCT01224730

Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Capecitabine
Drug: Placebo
Drug: Perifosine

First Posted Date: 2010-04-01

Last Posted Date: 2013-07-02

Lead Sponsor: AEterna Zentaris

Target Recruit Count: 468

Registration Number: NCT01097018

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
TN Oncology, Nashville, Tennessee, United States

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Neoplasm
Adult Anaplastic Astrocytoma
Adult Diffuse Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Glioblastoma
Adult Mixed Glioma
Adult Oligodendroglioma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Perifosine
Drug: Temsirolimus
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2010-01-18

Last Posted Date: 2021-07-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT01051557

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Perifosine + Capecitabine for Colon Cancer Patients

Phase 1

Completed

Conditions: Colon Cancer

Interventions: Drug: Perifosine
Drug: Capecitabine

First Posted Date: 2010-01-13

Last Posted Date: 2018-06-28

Lead Sponsor: AEterna Zentaris

Target Recruit Count: 10

Registration Number: NCT01048580

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Perifosine Placebo
Drug: Perifosine
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2009-10-27

Last Posted Date: 2018-02-09

Lead Sponsor: AEterna Zentaris

Target Recruit Count: 135

Registration Number: NCT01002248

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇮🇪
Keryx / AOI Pharmaceuticals Investigative Site, Dublin 7, Ireland

Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: perifosine

First Posted Date: 2009-04-01

Last Posted Date: 2013-05-27

Lead Sponsor: Daphne Friedman

Target Recruit Count: 16

Registration Number: NCT00873457

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma

Not Applicable

Completed

Conditions: Non Small Cell Lung Cancer
Solid Tumors
Metastatic Breast Cancer
Sarcomas

Interventions: Drug: Perifosine
Drug: Trastuzumab
Drug: Tamoxifen

First Posted Date: 2009-02-19

Last Posted Date: 2018-03-15

Lead Sponsor: AEterna Zentaris

Target Recruit Count: 10

Registration Number: NCT00847366

Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: perifosine

First Posted Date: 2008-10-21

Last Posted Date: 2017-08-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 38

Registration Number: NCT00776867

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

Phase 2

Completed

Conditions: Malignant Gliomas
CNS
Brain Cancer
Cancer

Interventions: Drug: Perifosine

First Posted Date: 2008-01-11

Last Posted Date: 2020-10-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 32

Registration Number: NCT00590954

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy